Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Showcasing Development & Application of Antibody Dual Drugs Conjugation (AD2C) Platform

By | 8 June 2026

Introducing the advantages and differentiation of AD2C platform for ADC development
Applying AD2C platform in development of anti-GPC3 ADCs with dual payloads for hepatocellular carcinoma treatment